Next Phase Newsletter

A family investment vehicle based in Australia invests in early-stage life science and digital health startups. The firm is focused on the Australian and U.S. markets with directors of the fund present in both countries. The fund is flexible in terms of investment size and capital structure and may co-invest or lead financing rounds.

The firm is interested in therapeutics, medtech and digital health companies. The group has a preference for companies that have some clinical data and is most interested in indications where the science is well-understood and the development path is straight-forward. The fund is particularly interested in repurposed and orphan drugs as well as other de-risked/accelerated regulatory pathways. The firm is most interested in ophthalmology, dermatology, microbiome-related technologies, the premature infant space and orphan indications.

The firm has a strong preference for experienced management teams, and prefers companies with modest valuations and capital needs so that their investment is impactful.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm is focusing on investing in behavioral health (addiction and mental health) companies. The firm is interested in digital health, services, health IT, and medical devices related to this area, and is currently looking to co-invest as part of a syndicate. The firm plans to invest in Seed and Series A rounds, with companies with proof-of-concept data. The firm will make $0.5-2.5M initial investments, and is currently focused primarily on the US, but will consider Canadian and European companies as well.

The firm will invest in services, health IT, medical device, and digital health companies that are related to behavioral health, which encompasses addiction and neuropsychiatric disorders such as (but not limited to) post-traumatic stress disorder, major depressive disorder, schizophrenia, bipolar disorder, and attention-deficit disorder. Within digital health, the firm will invest in patient or physician tools, training aids, telehealth, peer support tools, digital endpoints, and B2B platforms.

The firm is currently looking to co-invest, and may take a board or observer seat, depending on the deal size, portfolio priorities, and operational needs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investor, exclusively focused on the development of oncology therapies, makes selective investments in early-stage drug development companies targeting cancer therapies that can bring solid proof of concept to the table. Typically, the firm invests in incorporated companies from late seed stage to early series B. The investment size will vary, and it can range from 3 to 10 million dollars with the possibility of investing lower amounts for seed stage companies. The firm may make 3-4 investments in the next year, depending on the opportunity. The firm has no geographic restriction and is actively seeking new investment opportunities across the globe.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies, and is open to all types of therapeutic modalities and all indications within the oncology space, including platform technology that has a lead oncology therapeutic product. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Project will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

The firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of the portfolio companies. To this end, the firm has a several experts in oncology, intellectual property and drug development on the investment team and available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A conglomerate based in Asia with global interests in real estate development and investment, financial investment, hotels and shipping continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences. One business arm of this conglomerate is a global investment platform focusing on life sciences. Leveraging on the Group’s strong capital base and long term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, the group is starting to build significant presence in US and Greater China.

Within healthcare, the firm looks at cutting-edge biotech therapeutic technologies across small molecule, biologics, and novel therapies. The group focuses on oncology, brain diseases, as well as drug delivery platforms and genomic diagnostics. In terms of development stages, the group focuses on preclinical to early clinical stage assets that are seeking series A/B/C financing.

The firm looks for experienced and competent teams with sector expertise and track record of success. The firm prefers opportunities where they have already identified a healthcare-focused lead investor. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border venture capital firm with offices in USA and Asia currently invests from a fund closed in 2017. Its LPs includes major pharmaceutical companies. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. The firm is open to acting as either the lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large corporate’s strategic venture arm is focused on venture and growth stage investments in several verticals including healthcare, IT and energy. The group will make investments from $5M-$30M and is very flexible with structure and size, with approximately 80% of investments in the form of equity and the other 20% in debt. The group will both lead or co-invest and typically seeks board representation although it is not a requirement. The group is focused on companies in the United States, but may look at some international opportunities in select geographies.

The firm is interested in medical devices, healthcare services, digital health, and biopharma and the group is looking for de-risked opportunities in these areas. In the medical device space, the group is interested in devices that have achieved FDA approval and have reimbursement established. Digital health/healthcare IT companies should have commercial traction and a minimum of 10-20 paying customers. The group is looking for healthcare services companies that have proven their business model and are in need of growth capital. In the biopharma space, the group avoids opportunities with binary scientific, development, or clinical risk and is interested in areas such as specialty pharma, outsourced services, platform technologies, etc.

The firm places a large emphasis on high quality management teams and will work with companies with an incomplete management team as long as the key members of management are in place and have significant experience/expertise in the area they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm is a venture capital firm that invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.